NICE reschedules DES coverage meeting
This article was originally published in The Gray Sheet
Executive Summary
UK's National Institute of Health and Clinical Excellence (NICE) appraisal committee meeting to consider whether to move forward with preliminary recommendations that the National Health Service of England and Wales stop paying for drug-eluting stents, originally scheduled for Sept. 4, is rescheduled to Nov. 6 to allow conferees time to consider information from recently available economic models. The medical community in Britain is strongly opposing NICE's preliminary appraisal, making it more likely that the final policy will be toned down (1"The Gray Sheet" Sept. 3, 2007, p. 3)...
You may also be interested in...
Preliminary Recs Would Stop Payments For Drug-Eluting Stents In Britain
A committee meets this week to consider whether to move forward with preliminary recommendations for the Nation Health Service of England and Wales to stop paying for drug-eluting stents
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.